Kellie Ryan, MPH, discusses the importance of long-term follow-up with acalabrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
Kellie Ryan, MPH, director of Health Economics and Outcomes Research at AstraZeneca, discusses the importance of long-term follow-up with acalabrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
Results of a recent study found that one-third of patients with MCL and two-thirds of patients with CLL received prior treatment with ibrutinib (Imbruvica) before being treated with acalabrutinib (Calquence). Sixty percent of patients in the MCL and CLL cohorts were determined to be at high-risk of atrial fibrillation. These findings are interesting in terms of where physicians are thinking about products relative to their patients’ background, clinical, and demographic characteristics, says Ryan.
The key interest of the study is to understand the long-term, real-world outcomes of acalabrutinib and the long-term follow up in patients with MCL and CLL. Only 40% of patients had a follow up of ≥6 months. Researchers will continue monitor maturity of data and check-ins, preferably in 12 months, before looking at the safety and efficacy outcomes, concludes Ryan.